• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Butterfly Network Appoints New Leader

    BD Names Chairman of Board

    Interplex Acquires OCP Group

    FDA Clears a Portable Hemodialysis System

    Solid Growth Forecast for India's HER2 Amplification Tests Market
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    K-Tube Technologies

    Concise Engineering

    PTI Engineered Plastics Inc.

    FUTEK Advanced Sensor Technology Inc.

    Spectrum Plastics Group
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    Medbio LLC

    K-Tube Technologies

    Unicep

    PTI Engineered Plastics Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    FDA Approves First Breakthrough-Designated Next-Gen Sequencing IVD Cancer Test

    CMS also proposed coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers.

    FDA Approves First Breakthrough-Designated Next-Gen Sequencing IVD Cancer Test
    Related CONTENT
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    • Cognito Therapeutics’ Lead Product Receives FDA Breakthrough Device Designation
    • CMS Expedites Breakthrough Device Access; Industry Applauds
    • CareDx Partners with IDbyDNA
    • Preparing Your Design Controls for FDA Approval
    U.S. Food and Drug Administration12.01.17
    The U.S. Food and Drug Administration today approved the FoundationOne CDx (F1CDx), the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic (IVD) test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The Centers for Medicare & Medicaid Services (CMS) at the same time proposed coverage of the F1CDx. The test is the second IVD to be approved and covered after overlapping review by the FDA and CMS under the Parallel Review Program, which facilitates earlier access to innovative medical technologies for Medicare beneficiaries.
     
    “By leveraging two policy efforts aimed at expediting access to promising new technologies, we’ve been able to bring patients faster access to a breakthrough diagnostic that can help doctors tailor cancer treatments to improve medical outcomes and potentially reduce healthcare costs,” said FDA Commissioner Scott Gottlieb, M.D. “The FDA’s Breakthrough Device Program and Parallel Review with CMS allowed the sponsor to win approval for this novel diagnostic and secure an immediate proposed Medicare coverage determination within six months of the FDA receiving the product application.”
     
    Compared to other companion diagnostics previously approved by the FDA that match one test to one drug, the F1CDx is a more extensive test that provides information on a number of different genetic mutations that may help in the clinical management of patients with cancer. Additionally, based on individual test results, the new diagnostic can identify which patients with any of five tumor types may benefit from 15 different FDA-approved targeted treatment options. Its results provide patients and healthcare professionals access to all of this information in one test report, avoiding duplicative biopsies.
     
    “The F1CDx can help cancer patients and their healthcare professionals make more informed care decisions without the often invasive process of extracting tumor samples multiple times to determine eligibility for a single treatment or enrollment in a clinical trial,” said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health (CDRH). “With the run of one test, patients and healthcare professionals can now evaluate several appropriate disease management options.” 
     
    Today, CMS also issued a proposed national coverage determination of the F1CDx and other similar NGS IVDs for Medicare beneficiaries with advanced cancer (i.e., recurrent, metastatic or advanced stage IV cancer), who have not been previously tested using the same NGS technology and continue to seek further cancer therapy. The proposed national coverage determination provides coverage of NGS IVD tests to assist patients and their treating physicians in making informed cancer treatment decisions that improve health outcomes. Use of a test as a diagnostic also includes the ability to help patients and their treating physicians determine candidacy for cancer clinical trials.
     

    Foundation Medicine’s FoundationOne CDx, the first FDA-approved comprehensive companion diagnostic for solid tumors. Image courtesy of Business Wire.
    “Through parallel review and collaboration, we speed access to innovative diagnostics, so that doctors are better able to deliver the best quality care to their patients and patients have access to these state-of-the-art tests,” said Seema Verma, Administrator of CMS. “Our proposal establishes clear expectations, while at the same time delivering better outcomes for the people we serve.”
     
    This determination was made under the FDA-CMS Parallel Review Program, where the agencies concurrently review medical devices to help reduce the time between the FDA’s approval of a device and Medicare coverage. This voluntary program is open to certain premarket approval applications for devices with new technologies and to medical devices that fall within the scope of a Part A or Part B Medicare-benefit category and have not been subject to a national coverage determination.
     
    The F1CDx detects gene mutations that may be found in any solid tumor and this information can be used by physicians according to professional guidelines to manage cancer patients. Moreover, it can be used as a companion diagnostic to identify patients with specific mutations who may benefit from certain FDA-approved treatments for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer or ovarian cancer. Importantly, the F1CDx can detect genetic mutations that are indicated for multiple FDA-approved treatments, which extends beyond the previous “one test for one drug” model.
     
    The device works by sequencing DNA from a patient’s tumor sample to determine the presence of gene mutations and alterations. It also detects certain molecular changes (microsatellite instability and tumor mutation burden). Clinical performance of the test was established through a least burdensome means by comparing the F1CDx to previously FDA-approved companion diagnostic tests that are currently used to determine patient eligibility for certain treatments. Results indicated that the test’s ability to detect select mutation types (substitutions and short insertions and deletions) representative of the entire 324 gene panel is accurate approximately 94.6 percent of the time.
     
    The F1CDx had not been previously submitted for the FDA’s review because it is a laboratory-developed test, for which the agency has generally not enforced premarket review and other applicable requirements. However, at the test developer’s request, the FDA worked closely with them to help enter it into the agency’s newly established Breakthrough Device Program. Because of the test’s potential to consolidate multiple companion diagnostic claims for patients and healthcare providers in a single test, the F1CDx was granted Breakthrough Device designation. Under the Breakthrough Device Program, the FDA provides intensive interaction and guidance to the company on efficient device development, which expedites evidence generation and the agency’s review of devices that provide for more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases for which no approved or cleared treatment exists or that offer significant advantages over the existing standard of care.
     
    The FDA also reviewed the F1CDx application using a coordinated, cross-agency approach; the clinical review was conducted by FDA’s CDRH with support from FDA's Oncology Center of Excellence, while all other aspects of review and the final product approval determination was conducted by the FDA’s CDRH.
     
    The FDA granted approval for the F1CDx test to Foundation Medicine Inc.
    Related Searches
    • first
    • company
    • breast cancer
    • genes
    Related Knowledge Center
    • Diagnostics
    Suggested For You
    Boston Scientific Boston Scientific's Vercise Genus DBS Earns FDA Approval
    Cognito Therapeutics’ Lead Product Receives FDA Breakthrough Device Designation Cognito Therapeutics’ Lead Product Receives FDA Breakthrough Device Designation
    CMS Expedites Breakthrough Device Access; Industry Applauds CMS Expedites Breakthrough Device Access; Industry Applauds
    CareDx Partners with IDbyDNA CareDx Partners with IDbyDNA
    Preparing Your Design Controls for FDA Approval Preparing Your Design Controls for FDA Approval
    FDA OKs Hologic FDA OKs Hologic's Aptima HIV-1 Quant Dx Assay for HIV Diagnosis
    The Big Challenges of Medical Device Miniaturization The Big Challenges of Medical Device Miniaturization
    Sommetrics Sommetrics' aerSleep II Sleep Apnea Treatment Earns Breakthrough Designation
    How Design Controls Can Prevent Medical Device Recalls How Design Controls Can Prevent Medical Device Recalls
    Novocure Earns CE Mark for NovoTTF-100L System Novocure Earns CE Mark for NovoTTF-100L System
    QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test
    HeartHero Inc. Awarded ISO 13485 Certification HeartHero Inc. Awarded ISO 13485 Certification
    The Heart of the Matter: Trends in Cardiology The Heart of the Matter: Trends in Cardiology
    My 2020 Holiday Wish List My 2020 Holiday Wish List
    FDA Approves Boston Scientific FDA Approves Boston Scientific's Ranger Drug-Coated Balloon

    Related Breaking News

    • Diagnostics
      Abbott

      Abbott's Panbio Rapid COVID-19 Antigen Test Earns CE Mark for Two New Uses

      EU approves symptomatic screening and self-administered sample collection with nasal swab.
      Sam Brusco, Associate Editor 01.26.21

    • Diagnostics
      FDA OKs Canon Medical

      FDA OKs Canon Medical's AI-Powered, 90cm Bore CT

      Company claims the Aquilion Exceed LB CT offers the industry's largest bore opening.
      Sam Brusco, Associate Editor 01.21.21

    • Diagnostics
      RSIP Vision Announces Versatile Medical Image Segmentation Tool

      RSIP Vision Announces Versatile Medical Image Segmentation Tool

      Delivers efficient anatomical measurements and better treatment options.
      RSIP Visions 01.20.21


    • Diagnostics
      Thermo Fisher Buys Mesa Biotech for $450M

      Thermo Fisher Buys Mesa Biotech for $450M

      Mesa Biotech developed, commercialized a PCR-based rapid POC testing platform for detecting infectious diseases.
      PR Newswire 01.20.21

    • Diagnostics
      Owlstone Medical Introduces Breath Biopsy Panel for Respiratory Diseases

      Owlstone Medical Introduces Breath Biopsy Panel for Respiratory Diseases

      Supports research to distinguish between different types of chronic inflammatory airway diseases.
      Owlstone Medical 01.19.21

    • Cardiovascular | Diagnostics
      FDA OKs MRI for Impulse Dynamics

      FDA OKs MRI for Impulse Dynamics' Optimizer CCM Delivery Systems

      FDA clears potential hurdle for many heart failure patients.
      Business Wire 01.19.21


    • Diagnostics
      Rapid Antigen Tests Manufacturer Acquires BIOLAB

      Rapid Antigen Tests Manufacturer Acquires BIOLAB

      Deal will create jobs and increase Innova's U.S. COVID-19 test kit manufacturing capability.
      Innova Medical Group Inc. 01.14.21

    • Diagnostics
      PerkinElmer

      PerkinElmer's SARS-CoV-2 RT-PCR Assay Earns EUA for Asymptomatic Testing

      Gold-standard testing of individuals without COVID-19 symptoms key to controlling the spread.
      Business Wire 01.14.21

    • Diagnostics
      High-Volume COVID Antigen Test Receives FDA EUA

      High-Volume COVID Antigen Test Receives FDA EUA

      Ortho’s Vitros can run up to 130 tests per hour and helps address testing backlogs, supply shortages, and delayed results.
      Ortho Clinical Diagnostics 01.13.21


    • Diagnostics
      Researchers Develop Chip That Can Detect COVID-19 Antibodies in a Minute

      Researchers Develop Chip That Can Detect COVID-19 Antibodies in a Minute

      New diagnostic platform could be a valuable tool for detecting exposure to multiple viruses.
      Bob Marcotte, University of Rochester 01.13.21

    • Diagnostics
      Abbott to Supply Additional 30M COVID-19 Tests to U.S. Gov

      Abbott to Supply Additional 30M COVID-19 Tests to U.S. Gov't

      Company is in final stages of completing its self-funded capacity expansion across U.S. manufacturing sites.
      PR Newswire 01.13.21

    • Diagnostics
      Olympus and Hitachi Sign Five-Year Contract

      Olympus and Hitachi Sign Five-Year Contract

      Will jointly develop Endoscopic Ultrasound Systems.
      Olympus Corporation 01.11.21


    • Diagnostics
      ForaCare Suisse AG Launches COVID-19 Antigen Rapid Test

      ForaCare Suisse AG Launches COVID-19 Antigen Rapid Test

      Provides fast, accurate, and easy-to-interpret test results.
      PRNewswire 01.11.21

    • Diagnostics | Neurological
      FDA OKs Abbott

      FDA OKs Abbott's First-of-Its-Kind Rapid, Handheld TBI Test

      Produces a result within 15 minutes after a plasma sample is inserted.
      Abbott Laboratories 01.11.21

    • Diagnostics
      SARS-CoV-2 Mutation Prompts FDA Alert

      SARS-CoV-2 Mutation Prompts FDA Alert

      Impact remains low, but false negative results can occur with any molecular test.
      U.S. Food and Drug Administration 01.11.21


    Trending
    • Senseonics Forges Strategic Collaboration With Ascensia Diabetes Care
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Top 10 Trends In The Medical Device And Equipment Industry
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    • At-Home COVID-19 Test Kits Boosts Disease Monitoring Capabilities
    Breaking News
    • Butterfly Network Appoints New Leader
    • BD Names Chairman of Board
    • Interplex Acquires OCP Group
    • FDA Clears a Portable Hemodialysis System
    • Solid Growth Forecast for India's HER2 Amplification Tests Market
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    MIND and Mediterranean Diets Linked to Later Onset of Parkinson’s Disease
    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Coatings World

    Latest Breaking News From Coatings World

    Keyland Polymer UV Powder, LLC Launches UVMax Defender
    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Butterfly Network Appoints New Leader
    BD Names Chairman of Board
    Interplex Acquires OCP Group
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Adare Pharma Solutions Opens New Small-Scale Lab
    Stevanato Group Launches After-sales Service Offering
    X-Chem Acquires IntelliSyn and AviSyn
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Happi

    Latest Breaking News From Happi

    Nice-Pak Receives EPA Approval for Disinfectant Wipes
    Symrise Shares 2020 Sales Figures
    Harry’s Launches ‘Headquarters’
    Ink World

    Latest Breaking News From Ink World

    Epson Partner Creates Label Applicators for Pharmaceutical Products
    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Great Lakes Label debuts new website
    Epson partner creates label applicators for pharmaceutical products
    ACTEGA removes chemicals from laminating adhesives
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    American Made Production Equipment for Mask Manufacturers
    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login